IMJ 995
Alternative Names: IMJ-995Latest Information Update: 30 Dec 2022
At a glance
- Originator Novartis Pharmaceuticals
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 21 Dec 2022 Novartis Pharmaceuticals withdraw phase I trial in precursor-cell-lymphoblastic-leukaemia-lymphoma (NCT05168748)
- 30 Dec 2021 Preclinical trials in Precursor cell lymphoblastic leukaemia-lymphoma in Switzerland (IV) prior to December 2021 (Novartis Pharmaceuticals, December 2021)
- 23 Dec 2021 Novartis Pharmaceuticals plans a phase I trial for Precursor cell lymphoblastic leukaemia-lymphoma (Monotherapy, Second-line therapy or greater, In infants, In children, In adolescents, In adults, In the elderly) (IV) in February 2021 (NCT05168748)